secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001493152-23-041323
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)
-----------------------------------------------------------------------------

- Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.
- Operating profit of $1.9M, up 78.1% from prior-year period.
- Net income attributable to common shareholders: $14.9M, an 886% increase.
- Growth driven by launch of Elite Laboratories label product line in June 2023 quarter.
- Conference call scheduled for Nov 15, 2023 at 11:30 AM EST.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/0001493152-23-041323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223041323/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-041323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer